8:16 AM ET
10-Q
Financial Results
Neumora Therapeutics Q3 2026 Results: Net Loss of $34.4M, Loss Narrows
Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the prior year period. The company's cash and cash equivalents decreased significantly to $85.7 million as of September 30, 2026, compared to $182.5 million at the end of 2025, while total stockholders' equity fell to $18.6 million.
- Key figure
- Net loss $34.4M